Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 352 of 1,261
  1. US 10973871

    Ophthalmic compositions

    AURINIA PHARMACEUTICALS INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  2. US 10973862

    Bifidobacterium longum for treating obesity and associated metabolic disorders

    PrecisionBiotics Group Limited · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  3. US 10973841

    Compositions for the treatment of skin conditions

    FORTE SUBSIDIARY, INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  4. US 10973869

    Methods of treating cardiomyopathy associated with genetic disorders

    Compass Therapeutics LLC · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  5. US 10973861

    Compositions and methods

    Seres Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  6. US 10975375

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  7. US 10974041

    Neuromodulation device

    ACADEMISCH MEDISCH CENTRUM · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  8. US 10973844

    TALEN-based gene correction

    Regents of the University of Minnesota · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  9. US 10973813

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  10. US 10975393

    Engineered target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  11. US 10973805

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  12. US 10975094

    Heterocyclic compounds as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  13. US 10973764

    Neuroprotective liposome compositions and methods for treatment of stroke

    The Board of Regents of the University of Texas System · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  14. US 10973817

    Pharmaceutical compounds

    SENTINEL ONCOLOGY LIMITED · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  15. US 10973758

    Methods of eye treatment using therapeutic compositions containing dipyridamole

    O.D. Ocular Discovery Ltd. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  16. US 10973812

    Ataxia therapeutic compositions and methods

    Regents of the University of Minnesota · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  17. US 10975355

    Controlled induction of human pancreatic progenitors produces functional beta-like cells

    The Regents of the University of California · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  18. US 10975167

    Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  19. US 10975166

    Inhibitory antibodies against MMP-14

    The Regents of the University of California · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  20. US 10975139

    Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  21. US 10975150

    Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies

    Sutro Biopharma, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  22. US 10975158

    CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  23. US 10975365

    Di-enzymatic chimeric endolysin

    Government of the United States of America, as represented by the Secretary of Commerce · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  24. US 10973894

    Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

    The United States of America, as represented by the Secretary, Department of Health and Human · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.